REACH
19 October 2026
Cizzle Biotechnology Holdings plc
("Cizzle", "Cizzle Biotechnology", or the "Company")
Cizzle Biotechnology Shortlisted for Best Non-Therapeutic R&D Company of the Year at One Nucleus Awards 2026
Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, is pleased to highlight industry recognition and a showcase opportunity.
Highlights
- Cizzle shortlisted in the Best Non-Therapeutic R&D Company of the Year category at the One Nucleus Genesis Conference
- Selected by Independent expert biotechnology and journalist judging panel
- Shortlisting follows the Company’s research and development activities and commercialisation progress with its proprietary CIZ1B biomarker test for early stage lung cancer
- The Company will be showcased at the Genesis Conference, to key opinion leaders, innovators, investors and industry stakeholders within the Conference theme of “Maximising Returns from Life Science Innovation”
Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:
“We are delighted that Cizzle has been shortlisted for Best Non-Therapeutic R&D Company of the Year. Having spent many years developing our CIZ1B technology, this recognition comes at an important point as we progress the commercialisation of our lung cancer biomarker test.
“Being recognised by an independent panel of life sciences journalists and industry commentators is particularly encouraging, and I look forward to presenting Cizzle and our technology to the wider life sciences community at Genesis in December.”
About the One Nucleus Awards and Genesis Conference
The One Nucleus Awards recognise achievement across the life sciences sector, spanning research and development, investment, services and supporting activities. The Best Non-Therapeutic R&D Company of the Year category applies to companies undertaking research and development of new health technologies, including diagnostics, patient stratification, drug delivery and digital health.
Being shortlisted is a significant milestone for a life sciences company. It signals industry confidence and technological prestige across the biotechnology and healthcare ecosystem.
The finalists are selected by an expert panel of biotechnology experts and journalists from leading publications, raising Cizzle’s profile to investors and potential industry partners and adding independent credibility to the Company’s high value business proposition.
Candidate companies are assessed against published criteria covering innovation, potential impact on patient outcomes, financing and deals, leadership, and environmental, social and governance considerations.
Previous winners and finalists of the One Nucleus awards have gone on to experience major commercial acceleration, scaling their technologies, securing significant funding rounds, and landing transformative global partnerships.
The Company has also been invited to present at the Genesis conference to an audience specifically looking for collaboration and new deal flows. The "Non-Therapeutic" category provides a new focus to highlight the essential enablers of modern medicine.
The awards are presented by One Nucleus, a not for profit life sciences and healthcare membership organisation headquartered in Cambridge, as part of its flagship Genesis Conference. Now in its third decade, Genesis brings together key opinion leaders, R&D innovators, investors and industry stakeholders to discuss scientific innovation, commercialisation and investment opportunities. This year’s conference, themed “Maximising Returns from Life Science Innovation”, is expected to attract more than 400 delegates.
Being selected as a finalist, recognises our decades of research that has translated into clinical practice. The CIZ1B biomarker test is built on foundational research into cancer origins, and the CIZ1 protein’s role in epigenetic stability, led by Professor Dawn Coverley at the University of York. Her work led to the discovery of the CIZ1B protein variant and its strong association with lung cancer, and the development of molecular tools that can measure CIZ1B with high sensitivity in patients with early-stage lung cancer.
With validation in accredited laboratories the USA for clinical use, the Company’s licensing partner Cizzle Bio is now promoting the test to clinicians and patients. This will help with the detection of lung cancer in its early stages and improve a patient’s chance of survival. Similarly, Cizzle is also working with potential partners to bring the test to commercial and NHS laboratories in the UK and Europe.
Enquiries:
|
Cizzle Biotechnology Holdings plc |
Via IFC Advisory |
|
Allan Syms (Executive Chairman) |
|
Allenby Capital Limited (Financial Adviser) |
+44(0) 20 3328 5656 |
|
John Depasquale (Corporate Finance) |
|
|
Zeus (Corporate Broker) James Hornigold, Alex Slater (Investment Banking) Nick Searle (ECM) |
+44(0) 20 3829 5000 |
|
IFC Advisory Limited (Financial PR & IR) |
+44(0) 20 3934 6632 |
|
Tim Metcalfe |
|
|
Florence Staton |
About Cizzle Biotechnology
The CIZ1B biomarker is a naturally occurring variant of the cell nuclear protein CIZ1, which is linked with the preservation of epigenetic integrity. CIZ1B is highly associated with the presence of early-stage lung cancer and can be measured in small quantities of blood. The Company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer. In June 2026, the test was successfully accredited for use in the United States under the Clinical Laboratory Improvement Amendments (CLIA) at OmniHealth Diagnostics, providing a regulated laboratory route to market that enables licensed US healthcare providers to order the test.
Cizzle has entered into commercial royalty-bearing licensing arrangements covering North America and the Caribbean and continues to work with commercial partners and centres of excellence in cancer care to support the adoption of its proprietary diagnostic technologies in the UK and elsewhere.
Cizzle was admitted to the Official List and Main Market of the London Stock Exchange in May 2021.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
About One Nucleus
One Nucleus’s vision is to supercharge bio-innovation.
Its mission is to inspire, inform, and implement by connecting bio-innovation leaders and their companies with knowledge, investment, and deal-flow opportunities in a capital-efficient way, supporting organisations from start-up through to exit.
As a not-for-profit life science membership organisation, One Nucleus brings together stakeholders from across the sector to help them achieve their aspirations on the global stage.
Genesis
For more information please see https://www.genesisconference.com/about-genesis
#ONAwards26
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.